SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517490-24-00

Enrollment

Registered

2026-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Brief summary

Progression-Free Survival (PFS) based on investigator assessment per RECIST v1.1.

Detailed description

Overall Response (OR) as Measured by Overall Response Rate (ORR) based on investigator assessment per RECIST v1.1., Duration of Response (DoR) based on investigator assessment per RECIST v1.1., Disease Control (DC) based on investigator assessment per RECIST v1.1., OS

Interventions

DRUGCARBOPLATIN

DRUGETOPOSIDE

DRUGATEZOLIZUMAB

DRUGABBV-706

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS) based on investigator assessment per RECIST v1.1.	—

Secondary

Measure	Time frame
Overall Response (OR) as Measured by Overall Response Rate (ORR) based on investigator assessment per RECIST v1.1., Duration of Response (DoR) based on investigator assessment per RECIST v1.1., Disease Control (DC) based on investigator assessment per RECIST v1.1., OS	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 20, 2026